Moreland Mary K 4
4 · ABBOTT LABORATORIES · Filed Feb 23, 2022
Insider Transaction Report
Form 4
Moreland Mary K
EXECUTIVE VICE PRESIDENT
Transactions
- Sale
Common shares without par value
2021-02-22$119.31/sh−400$47,723→ 86,965 total - Award
Common shares without par value
2022-02-18+15,813→ 88,158 total - Award
Option (right to buy)
2022-02-18+73,696→ 73,696 totalExercise: $117.58From: 2023-02-18Exp: 2032-02-17→ Common Shares (73,696 underlying) - Tax Payment
Common shares without par value
2022-02-22$116.79/sh−793$92,614→ 87,365 total
Holdings
- 10,986(indirect: By Trust)
Common shares without par value
Footnotes (4)
- [F1]These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.3003 to $119.3100, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]Balance in the Abbott Laboratories Stock Retirement Trust as of February 18, 2022.
- [F4]Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 24,565 on February 18, 2023, 24,565 on February 18, 2024, and 24,566 on February 18, 2025.